|
Synonyms: AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
ivonescimab is an approved drug (China (2024))
Compound class:
Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It was designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [5].
|
| References |
|
1. Dhillon S. (2024)
Ivonescimab: First Approval. Drugs, 84 (9): 1135-1142. [PMID:39073550] |
|
2. Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, Underhill C, Wang W, Wang ZM, Li B, Xia Y, Coward JIG. (2024)
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer, 12 (4). [PMID:38642937] |
|
3. HARMONi-A Study Investigators. (2024)
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial. JAMA, Online ahead of print. DOI: 10.1001/jama.2024.10613 |
|
4. Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W et al.. (2023)
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine, 62: 102106. [PMID:37593227] |
|
5. Zhong T, Huang Z, Pang X, Jin C, He X, Xia Y, Li B, Min J. (2022)
AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. J Immunother Cancer, 10 (Suppl 2): A546–A547 Abstract. DOI: 10.1136/jitc-2022-SITC2022.0521 |
